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Objectives. We investigated the hypothesis that abciximab
might lead to a differential effect among patients with different
lesion morphologies; hence, its cost/benefit ratio would be opti-
mized if it were used selectively on the basis of baseline angio-
graphic findings.
Background. Major complications of coronary angioplasty oc-
cur in 4% to 9% of patients. In the Evaluation of 7E3 for the
Prevention of Ischemic Complications (EPIC) and Evaluation of
PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa
Receptor Blockade (EPILOG) trials, abciximab decreased the
ischemic complications after intervention by 35% to 56%. How-
ever, the cost of this agent is appreciable, and there remain
concerns about the safety of its readministration.
Methods. There were 1,362 patients in EPIC and 2,792 patients
in EPILOG randomized to either bolus plus an infusion of
abciximab or placebo, administered with aspirin and heparin at
the time of the coronary intervention. Data from these studies
were combined, and a differential effect of abciximab in relation to
baseline lesion morphology on 30-day risk of death, myocardial
infarction or urgent intervention was investigated using the
Breslow Day test for statistical interaction.
Results. Abciximab consistently reduced the relative risk of
complications across all lesion morphologies studied, with the
possible exception of patients treated with degenerated saphenous
vein grafts (risk with placebo 16.3% vs. risk with abciximab 18.6%,
Breslow Day test for interaction, p 5 0.08). However, the absolute
reduction of risk was somewhat greater in patients with more
complex B2 or C lesions (7.6% and 5.8%, respectively) than in
patients with morphologically simpler A or B1 lesions (3.7% and
3.2%, respectively).
Conclusions. The reduction of early adverse ischemic events
associated with angioplasty by abciximab occurs largely indepen-
dent of pretreatment morphology.
(J Am Coll Cardiol 1998;32:1619–23)
©1998 by the American College of Cardiology
The clinical benefit of angioplasty (1,2) remains limited by
early dissection or thrombus-mediated vessel closure (4% to
9%) (3–6) and by later restenosis requiring repeat revascular-
ization (20% to 30%) (7,8). Early complications, in particular,
have been correlated with certain features of the lesion
treated, such as angiographically visible thrombus, lesion an-
gulation and length (9–11). Blockade of the platelet surface
glycoprotein (GP) IIb/IIIa receptor with abciximab has been
convincingly demonstrated in the Evaluation of 7E3 for the
Prevention of Ischemic Complications (EPIC) (12) and the
Evaluation of PTCA To Improve Long-term Outcome by c7E3
GPIIb/IIIa Receptor Blockade (EPILOG) (13) trials to reduce
the ischemic complications of angioplasty by 35% to 56%.
Although the enhanced bleeding complications seen in the
EPIC trial were eliminated in the EPILOG trial by a reduction
in concomitant heparin dosage and early sheath removal, a
strategy of generalized abciximab administration remains lim-
ited by its cost and by concerns about the risk of readminis-
tration (14).
This study was undertaken to ascertain whether treatment
with abciximab, when used with balloon angioplasty or direc-
tional coronary atherectomy, might have had a differential
effect on patients with different lesion morphologies—because
if it did, this potent agent could be used to treat patients with
the most to gain. We hypothesized that patients with lesions of
complex or thrombus-associated morphologies might derive
heightened benefit from platelet GPIIb/IIIa inhibition.
Methods
Study groups and treatment protocols. The study proto-
cols have been described in detail elsewhere (12,13). In brief,
in the EPIC study, 2,099 patients at increased risk for ischemic
complications of angioplasty or atherectomy by virtue of
clinical presentation (unstable angina, postinfarct angina or
acute myocardial infarction [MI]) or lesion morphology (9,10)
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gave written informed consent and were randomized to stan-
dard therapy (aspirin plus heparin), standard therapy plus
intravenous bolus abciximab (0.25 mg/kg body weight) or
standard therapy plus bolus (0.25 mg/kg) and infusion (10
mg/min for 12 h) abciximab administered in a double-blind
fashion. In the EPILOG study, 2,792 patients eligible for
angioplasty or atherectomy, and without unstable angina with
associated electrocardiographic (ECG) changes or acute MI
within the previous 24 h (the group shown to benefit most in
the EPIC study) gave written informed consent and were
randomized to bolus (0.25 mg/kg) and infusion (0.125 mg/kg
per min [maximum 10 mg per min] for 12 h) of abciximab and
one of two heparin regimens (target activated clotting time
[ACT] $300 s or $200 s) or aspirin plus heparin (target ACT
$300 s) therapy only. For the purposes of this analysis, because
patients in the bolus-only arm in EPIC did not derive signifi-
cant clinical benefit, the bolus plus infusion groups from both
studies were combined, and the effect of therapy was assessed
against that seen in the combined placebo groups from the two
studies.
Study end points. Data were collected by study coordina-
tors on case report forms, and the veracity of source documen-
tation was assured by study monitors before data entry. Both
groups had no knowledge of the treatment received.
The primary end point of this study was identical to that in
the EPILOG study and was a slight modification of the primary
end point in EPIC—a composite of all-cause mortality, non-
fatal MI and repeat revascularization for acute coronary
ischemia occurring within the first 30 days after randomization.
Events were classified by a consensus of at least two members
of an independent end points committee that had no knowl-
edge of the patients’ randomized treatment allocation.
Angiographic analysis. Preintervention lesion characteris-
tics and angiographic findings were reported by the investiga-
tors, using the following definitions: angulation (,45°, 45 to
60°, .60°), lesion calcification (none, mild, moderate, severe),
lesion contour (smooth, irregular, ulcerated), lesion eccentric-
ity, lesion length (,10 mm, 10 to 20 mm, .20 mm), modified
American College of Cardiology/American Heart Association
(ACC/AHA) lesion classification (10), ostial location, percent
diameter stenosis (calipers), presence of a side branch (none,
1.0 to 1.9 mm, 2.0 to 2.4 mm, $2.5 mm), proximal tortuosity
(none, two or more bends of $60° or one 90° bend, two or
more 90° bends), Thrombolysis In Myocardial Infarction flow
grade and thrombus (absent, possible, present). Definitions of
the characteristics that are not explicitly defined have been
previously published (9,10).
Statistical analysis. Continuous data are presented as the
mean value and interquartile range, and categoric variables are
presented as percentages. For patients with more than one
treated lesion (n 5 702, 25.2%), a morphologic variable was
considered to be present if it was apparent for any treated
lesion in that patient. Separate and pooled univariate and
multivariate analyses from the EPIC and EPILOG trials for
each candidate morphologic variable were performed. Odds
ratios and p values for the benefit of abciximab for each lesion
morphology were calculated based on the Cochran–Mantel–
Haenzel statistic. Breslow Day tests were performed to test for
the possibility of an interaction between treatment and lesion
morphology and to ascertain if there was a differential treat-
ment effect in the EPIC and EPILOG trials. Using this test,
p , 0.05 suggests a nonuniformity of benefit between mor-
phologies or clinical trials, whichever is being tested. For all
statistical tests, p , 0.05 was considered significant, although
an assessment of the number of patients studied, as well as the
relative and absolute risk reductions, was also considered.
However, p values # 0.10 are provided to assist in interpreta-
tion of the results.
Results
Patient characteristics and outcome. Baseline clinical and
end point data for the patients studied are presented in Table
1. The majority of patients were middle aged and male. By
virtue of the inclusion criteria in the EPIC trial, refractory
acute ischemic syndromes were less common in that study than
in EPILOG. In the EPIC trial, balloon angioplasty was per-
formed as sole treatment in 90% of the patients, whereas 4%
Abbreviations and Acronyms
ACC/AHA 5 American College of Cardiology/American Heart
Association
ACT 5 activated clotting time
EPIC 5 Evaluation of 7E3 for the Prevention of Ischemic
Complications (trial)
EPILOG 5 Evaluation of PTCA To Improve Long-term Outcome
by c7E3 GPIIb/IIIa Receptor Blockade (trial)
GP 5 glycoprotein
Table 1. Baseline Characteristics
EPIC
(n 5 1,362)
EPILOG
(n 5 2,792)
Mean age in years (interquartile range) 61 (52,69) 63 (51,69)
Diabetes (%) 24 23
Hypertension (%) 54 59
Indication for procedure
Refractory unstable angina (%)* 23 0†
Non-refractory unstable angina (%) 19 68
Stable angina (%) 58 32
Male gender (%) 72 72
Previous bypass surgery (%) 15 13
Previous PTCA (%) 22 25
Smoking, current (%) 34 33
Median weight (kg) 82.5 84
*Any of 1) angina at rest with electrocardiographic (ECG) changes; 2)
recurrent angina with ischemic ECG changes while in the hospital, not respon-
sive to standard pharmacologic intervention; or 3) early postinfarction angina
(within 7 days of myocardial infarction with accompanying ECG changes). †Due
to striking efficacy of treatment in this subgroup in EPIC, these patients were
excluded from EPILOG. PTCA 5 percutaneous transluminal coronary angio-
plasty.
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had directional coronary atherectomy, 5% had both angio-
plasty and atherectomy and 0.9% had bailout stents. In the
EPILOG study, those figures were 90%, 2% and 4%, respec-
tively. In addition, elective stenting (for suboptimal results)
was performed in 2.0%, rotational atherectomy in 0.5%,
excimer laser in 0.3% and extraction atherectomy in 0.2% of
patients as primary therapy. Bailout stenting was used as an
adjunct procedure in 13% of patients in the EPILOG trial.
The overall incidence of the composite adverse outcome in
the placebo and abciximab groups was 12.1% and 6.1%,
respectively (p , 0.001). In the placebo group, the incidences
of death, MI, urgent bypass surgery and urgent angioplasty
were 1.2%, 8.6%, 2.5% and 4.0%, respectively. In the abcix-
imab group, percentages were 0.7%, 4.1%, 1.1% and 1.2%,
respectively.
Effect of abciximab treatment on major ischemic compli-
cations. The absolute risk of major ischemic complications
and the odds ratios with Cochran–Mantel–Haenzel and
Breslow Day statistics for the different lesion morphologies are
presented in Figure 1 and Table 2. Importantly, the 95%
confidence intervals for the odds ratios and the Cochran–
Figure 1. Treatment effect of abciximab on 30-day adverse outcome
for various lesion morphologies. LL 5 lesion length; Deg SVG 5
degenerated saphenous vein graft.
Table 2. Combined Trial Results for the 30-Day Death/Myocardial Infarction/Urgent Intervention
Outcome by Case Report Form (CRF)-Defined Lesion Morphology
n
Odds
Ratio* 95% CI
p Values
CMH*
BD† Trial
Interaction
BD† Treatment
Interaction
ACC/AHA lesion classification
Type C 751 0.61 (0.39–0.9) 0.034 NS NS
Type B2 2,485 0.93 (0.30–0.52) ,0.001 0.091 NS
Type B1 589 0.56 (0.25–1.22) NS NS NS
Type A 298 0.55 (0.19–1.65) NS NS NS
Lesion length $10 mm 1,896 0.54 (0.39–0.74) ,0.001 NS NS
Eccentric lesion 2,944 0.44 (0.34–0.56) ,0.001 0.049 NS
Moderate to excessive tortuosity 961 0.49 (0.33–0.72) ,0.001 0.048 NS
Angulation .45° 761 0.42 (0.27–0.66) ,0.001 NS NS
Irregular contour 2,312 0.46 (0.34–0.60) ,0.001 NS NS
Ostial lesion 380 0.58 (0.31–1.06) 0.078 NS NS
Calcified lesion 452 0.27 (0.15–0.48) ,0.001 NS NS
Thrombus present 799 0.43 (0.27–0.68) ,0.001 NS NS
Total occlusion 458 0.73 (0.39–1.36) NS NS NS
Bifurcation 365 0.55 (0.31–0.99) 0.047 0.018 NS
Degenerated saphenous vein graft 102 1.11 (0.39–3.20) NS NS 0.083
*Odds ratio and p value based on the Cochran–Mantel–Haenzel (CMH) statistics (see text for details). †Breslow Day
(BD) p values (see text for details). ACC/AHA 5 American College of Cardiology/American Heart Association; CI 5
confidence interval.
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Mantel–Haenzel determined p values are dependent on both
the relative difference of the incidence of adverse events
between the two treatment groups and on the number of
patients studied. In general, the beneficial effect of abciximab
extended across all lesion morphologies examined (with the
possible exception of degenerated vein grafts, which appeared
to possibly be resistant, Breslow Day test, p 5 0.083), with the
relative reduction in adverse events ranging from 73% (calci-
fied lesions) to 27% (total occlusions). Expressed as an abso-
lute reduction in adverse events, the beneficial abciximab effect
was noted with all lesion morphologies, except for degenerated
vein grafts, and had its most striking beneficial effect in
angulated lesions (absolute reduction of 10.5%, p , 0.001),
bifurcation lesions (absolute reduction of 11.0%, p 5 0.047)
and calcified lesions (absolute reduction 13.0%, p , 0.001).
The absolute benefit of abciximab in preventing adverse effects
at 30 days was somewhat more prominent for complex type B2
or C lesions (7.6% and 5.8%, respectively) than for simpler
type A or B1 lesions (3.7% and 3.2%). Notably, the absolute
reduction in adverse events noted with patients treated with
thrombus-containing lesions was 6.3% (p , 0.001). Possible
intertrial treatment differences, as assessed by Breslow Day
testing, were noted for bifurcation lesions and possibly for
tortuous and eccentric lesions also. Analyses limited to pa-
tients with a single treated site (n 5 3,452) yielded essentially
the same results with regard to the interaction between
treatment and lesion morphology as the overall analysis.
Discussion
Background. Many individual (e.g., lesion length [9]) or
amalgamated lesion groupings (e.g., modified ACC/AHA le-
sion classification B2 or C [10,11]) have been correlated with
an increased risk of ischemic complications with angioplasty or
directional coronary atherectomy. When a mechanism for
ischemia can be identified, these complications are most
frequently due to arterial dissection (4), but thrombus is often
superimposed (14,15) and sometimes primary (4). Certain
lesion types have been shown to be at increased risk of
dissection-mediated ischemia, and other lesion types appear to
be at increased risk of thrombus-induced ischemia. Those
apparently at particular risk of dissection include long, angu-
lated, calcified or de novo lesions. Those at heightened risk of
thrombus-mediated closure include preexistent thrombus ob-
served at angiography, degenerated saphenous vein grafts and
eccentric lesions (16).
Abciximab, by providing powerful blockade of the platelet
GPIIb/IIIa receptor modulating platelet aggregation, was
shown in both the EPIC and EPILOG trials to dramatically
reduce ischemic complications of angioplasty and related
interventions. Were it not for the cost of this agent and
concerns about the risk of readministration (thrombocytope-
nia), one could cogently argue that all patients undergoing
balloon angioplasty should have adjunctive abciximab therapy.
Given these potential limitations, however, it would be advan-
tageous to use this agent for patients most likely to benefit. The
relative beneficial effect of abciximab on patients with varied
lesion morphologies has not been studied, except in highly
selected lesion types (17–19). However, one might postulate
that lesions at greatest risk of thrombotic closure might benefit
most. In contrast, the frequent association of deep dissection
with thrombus might lead one to argue that all lesion types
would benefit more or less equally.
Results. In this evaluation involving 4,154 patients, we
were unable to discern a strong differential effect of abciximab
dependent on angiographically defined lesion type, with the
possible exception of degenerated saphenous vein grafts, which
tended to have less benefit. It should be noted, however, that
this morphology was present in the least number of patients
studied (n 5 102), and therefore our study had the least power
to detect a beneficial or detrimental effect in this group. The
large benefit in dissection-prone lesions (angulated, bifurca-
tion, calcified) is particularly noteworthy. One would infer that
although the more complex lesion types (B2 and C) might
more often yield dissection-mediated ischemia, thrombus plays
a major role in most ischemic complications of balloon angio-
plasty in both simple and complex lesions.
Effect in degenerated saphenous vein grafts. If there is
indeed a lessened beneficial effect for patients with degener-
ated vein grafts, one might postulate 1) that the stimulus for
thrombosis in this situation was more dependent on the
coagulation cascade per se than on platelet activation; 2) that
the stimulus for platelet activation was greater in such patients
so as to overwhelm the partial blockade induced by abciximab;
3) or that the etiology of complications in these patients might
be related more to embolization of the friable atheromatous
plaque than to thrombosis per se. In this regard, it is notable
that in an ex vivo system, Fernandez-Ortiz et al. (20) found that
platelet deposition was four to five times greater when platelets
were exposed to sections of human aorta with atheromatous
core (soft core with abundant cholesterol crystals) as compared
with collagen or foam cell rich material. Such atheroma are
typically seen in degenerated vein grafts (21). The possible
lesser beneficial effect for patients with total occlusions, al-
though not approaching statistical significance, also merits
comment. The older thrombi that typically complete a vessel’s
occlusion, which likely were frequently present in this patient
group (because acute occlusions were very uncommon in this
patient group), may be somewhat more resistant to the bene-
ficial effects of abciximab on platelet deposition or even
platelet disaggregation (22).
Study limitations. It is important to understand several
limitations of this study. First, although the number of lesions
treated is large in comparison to many other studies, the power
to detect treatment–lesion type interactions is modest. Second,
it is recognized that the interobserver variability for categoriz-
ing a lesion’s characteristics is considerable, with kappa values
often in the range of 0.30 to 0.70, and lesion characteristics
were assessed at the clinical site rather than at a core angio-
graphic laboratory (10,23). This may undermine our power to
detect special benefit in patients with certain lesion types, but
reflects the “real world” assessment of lesion morphology.
1622 ELLIS ET AL. JACC Vol. 32, No. 6
ABCIXIMAB–MORPHOLOGY INTERACTION November 15, 1998:1619–23
Third, the influence of abciximab on outcome in patients
receiving stents cannot be defined. Apparent benefit has been
previously reported in the setting of bailout stenting (24). Our
results, therefore, are germane for the 30% to 50% of patients
not treated with stents. Fourth, there appear to be some
potential differences in the relative treatment effect between
patients from the EPIC and EPILOG trials. By virtue of the
inclusion criteria of EPIC, patients more frequently had re-
fractory unstable angina in EPILOG, potentially explaining the
possible differential effect noted. It is unlikely that the minor
differences in treatment regimen between the two studies had
any effect on this finding. It is also possible that one or more of
these findings relates to the numerous statistical tests per-
formed in an attempt to determine interactions. Fifth, as
alluded to, we recognize that multiple statistical tests were
performed to analyze the possibility of treatment interactions
with these 11 specific lesion morphologies. The likelihood of a
spurious finding (statistical type I error) is thereby heightened,
and we would urge caution in the interpretation of borderline
interaction-related p values (0.01 to 0.05). Finally, we recog-
nize that a long-term reduction in ischemic events with abcix-
imab in nondiabetic patients has also been reported from these
studies, and the data we have analyzed pertain only to short-
term outcome.
Study implications. It appears, therefore, with the ac-
knowledgement of the limitations noted, that the use of
abciximab in conjunction with angioplasty should not be
strongly predicated on angiographic morphology of the le-
sion(s) to be treated. As unstable symptoms also do not predict
benefit (25), other issues such as the likely consequences of
vessel closure (26) and bleeding risk (19) should be considered
carefully in the decision to use this agent. The possible
diminished effect noted with treatment of degenerated saphe-
nous vein grafts should be analyzed in other patient groups.
The authors express their gratitude to Ms. Patti Durnwald for her expert
secretarial assistance in the preparation of this report.
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